Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveJindal Steel Reports Q2 Consolidated Net Profit of 7.74 Billion Rupees

Live News EQUITY FLASH M impact Oct 23, 2026, 09:42 AM UTC

Jindal Steel Reports Q2 Consolidated Net Profit of 7.74 Billion Rupees

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

JINDALSTEL

Related stories

World Acceptance Reports Second-Quarter Revenue of $139.2M M impact | EQUITY | Oct 23, 2026, 11:39 AM UTC Novartis Kisqali Cuts Death Risk 19% After Six Years, Data Shows Trial data presented at the European Society for Medical Oncology congress in Madrid show Kisqali helped extend survival for women with a form of high-risk, early-stage breast canc L impact | EQUITY | Oct 23, 2026, 11:35 AM UTC BASF Increases Bid for Evonik to More Than €11 Billion M impact | EQUITY | Oct 23, 2026, 11:35 AM UTC Rithm Capital Reports Third-Quarter 2026 Results Rithm Capital reported results for the quarter ended September 30, 2026. CEO Michael Nierenberg described the results as strong. M impact | EQUITY | Oct 23, 2026, 11:33 AM UTC Takeda Phase 3 Trial Shows OS and PFS Benefits in Gastric Cancer Takeda said Phase 3 G-HOPE-001 met both primary endpoints, with arcotatug tavatecan (TAK-921) showing statistically significant overall and progression-free survival benefits versu M impact | EQUITY | Oct 23, 2026, 11:30 AM UTC Bristol Myers Squibb Phase 3 Shows 59% Lower PFS Risk vs Chemotherapy Izalontamab brengitecan reduced the risk of progression or death by 59% in HR+/HER2- breast cancer. Median progression-free survival was 8.2 months versus 4.0 months with chemother M impact | EQUITY | Oct 23, 2026, 11:30 AM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.